Tezspire Approved in EU for CRSwNP

US FDA Approves Tezspire in CRSwNP

Positive CHMP opinion for subcutaneous Saphnelo

Agreement with US Govt to lower medicine prices

Baxdrostat met primary endpoint in Bax24 Ph3 trial

Datroway improved OS and PFS in TROPION-Breast02

Total Voting Rights

Enhertu improved IDFS in early BC in DB-05

AZN harmonises listing structure

Director/PDMR Shareholding

Koselugo recommended for EU approval

Tezspire Recommended for Approval in EU for CRSwNP

Update on RESOLUTE Phase III trial

Saphnelo met primary endpoint in TULIP-SC

Total Voting Rights

Holding(s) in Company

Holding(s) in Company

Holding(s) in Company

Director/PDMR Shareholding

Holding(s) in Company

Holding(s) in Company

Update on anselamimab in AL amyloidosis

Baxdrostat met primary endpt in BaxHTN PhIII trial

Imfinzi approved in the EU for bladder cancer

Total Voting Rights

Datroway approved in US for EGFRm lung cancer

Holding(s) in Company

AstraZeneca enters into collaboration with CSPC

Director/PDMR Shareholding

Fixed-duration Calquence approved in EU for 1L CLL

Block listing Interim Review

Total Voting Rights

Imfinzi recommended in EU for bladder cancer

Director/PDMR Shareholding

Director Declaration

Acquisition of EsoBiotec completed

Imfinzi improved DFS in early bladder cancer

Enhertu improved pCR in early-stage breast cancer

Calquence combination approved in EU for 1L MCL

Breztri met primary endpoints in Ph3 asthma trials

Director/PDMR Shareholding

Total Voting Rights

Fixed-duration Calquence recommended in EU for CLL

Update on CAPItello-280 Phase III trial

1st Quarter Results

Enhertu combination improved PFS in 1L HER2+ mBC

Result of AGM

Enhertu approved in EU in post-ET breast cancer

Imfinzi approved in EU for AEGEAN

Total Voting Rights

Calquence recommended for EU approval in 1L MCL

Imfinzi approved in the US for bladder cancer

AZN invests $2.5bn in Beijing R&D & manufacturing

Eneboparatide Phase III trial met primary endpoint

AstraZeneca to acquire EsoBiotec

Imfinzi approved in EU for limited-stage SCLC

Director/PDMR Shareholding

Notice of AGM

Imfinzi improved EFS in early-stage gastric cancer

Director/PDMR Shareholding

Director/PDMR Shareholding

Total Voting Rights

Imfinzi recommended for EU approval for AEGEAN

Enhertu recommended in EU in post-ET breast cancer

Camizestrant improved PFS in 1L HR+ breast cancer

Holding(s) in Company

Annual Financial Report

Directorate Change

Final Results

Total Voting Rights

Imfinzi recommended for EU approval for LS-SCLC

Enhertu approved in US for breast cancer post ET

Dato-DXd approved in US for HR+ breast cancer

Calquence combination approved in US for 1L MCL

Total Voting Rights

Dato-DXd NSQ NSCLC application withdrawn in EU

Tagrisso approved in EU based on LAURA trial

Directorate Change

Imfinzi approved in US for limited-stage SCLC

AstraZeneca appoints Iskra Reic EVP International

Block listing Interim Review

Total Voting Rights

Truqap improved rPFS in advanced prostate cancer

Director/PDMR Shareholding

Tagrisso recommended for EU approval - LAURA

Director/PDMR Shareholding

Director/PDMR Shareholding

Director/PDMR Shareholding

KOMET Phase III trial met primary endpoint

9M and Q3 2024 Results

Dato-DXd new BLA submitted, NSQ BLA withdrawn

AstraZeneca invests $3.5 billion in US

Tezspire nasal polyps trial met primary endpoints

AZN share price movement

Total Voting Rights

AZN China President under investigation

Wainzua recommended for approval in the EU

AstraZeneca licenses lipid lowering Lp(a) asset

Total Voting Rights

Tagrisso US approval in unresectable lung cancer

Final OS results reported for TROPION-Breast01

Fasenra recommended for EU approval in EGPA

Fasenra EGPA US FDA approval

Director/PDMR Shareholding

Total Voting Rights

Imfinzi approved in US for resectable lung cancer

Total Voting Rights

ODAC reviewed Imfinzi in resectable lung cancer

Half-year Report

Acquisition of Amolyt Pharma completed

Total Voting Rights

Lynparza & Imfinzi positive CHMP in endometrial

Update on Imfinzi ADJUVANT BR.31 trial

Imfinzi improved EFS and OS in bladder cancer

Update on CAPItello-290 Phase III trial

Imfinzi approved in the US for endometrial cancer

Director/PDMR Shareholding

Acquisition of Fusion completed

Block listing Interim Review

Total Voting Rights

Tagrisso plus chemo recommended for approval in EU

Dato-DXd improved OS in nonsquamous lung cancer

AstraZeneca to deliver $80bn revenue by 2030

SUPERNOVA Trial Met COVID-19 prevention endpoint

Director/PDMR Shareholding

AstraZeneca completes Cellectis equity investment

Calquence combination improved PFS in 1L MCL

Total Voting Rights

Truqap recommended for EU breast cancer approval

Enhertu improved PFS in HER2-low and ultralow

1st Quarter Results

Result of AGM

AstraZeneca increases 2024 dividend by 7%

Enhertu approved in US for HER2+ solid tumours

Imfinzi improved OS & PFS in limited-stage SCLC

Total Voting Rights

FDA accepts Dato-DXd BLA for breast cancer

Voydeya approved in US

Ultomiris approved in the US for NMOSD

AstraZeneca to acquire Fusion

AstraZeneca to acquire Amolyt

Director/PDMR Shareholding

Notice of AGM

Director/PDMR Shareholding

Director/PDMR Shareholding

EMA validates Dato-DXd MAAs for NSQ NSCLC and BC

Total Voting Rights

Voydeya recommended for EU approval

Acquisition of Gracell completed

Director/PDMR Shareholding

AstraZeneca prices a $5bn bond offering

Annual Financial Report

AstraZeneca completes acquisition of Icosavax

Tagrisso improved PFS in Stage III lung cancer

FDA accepts Dato-DXd BLA for nonsquamous NSCLC

Tagrisso plus chemo approved in US for lung cancer

Final Results

Total Voting Rights

Total Voting Rights

AstraZeneca acquires Gracell

Wainua (eplontersen) granted first US FDA approval

Director/PDMR Shareholding

AstraZeneca to acquire Icosavax

Block listing Interim Review

Total Voting Rights

Discontinuation of two CRYSTALIZE evidence trials

Director/PDMR Shareholding

Truqap approved in US for HR+ breast cancer

Update on PACIFIC-2 Phase III trial for Imfinzi

Director Declaration

9M and Q3 2023 results

Imfinzi combination improves PFS in liver cancer

Agreement with Eccogene for clinical stage GLP-1RA

Total Voting Rights

AstraZeneca cell & gene therapy deal w/ Cellectis

AstraZeneca settles Nexium liability litigations

Total Voting Rights

Dato-DXd improved PFS in breast cancer

Alexion completes Pfizer gene therapy agreement

Enhertu recommended in EU for HER2-mutant NSCLC

Fasenra Phase III EGPA trial met primary endpoint

Update on US review of Ultomiris for NMOSD

Total Voting Rights

Alexion enters gene therapy agreement with Pfizer

Half-year Report

Total Voting Rights

Dato-DXd significantly improved PFS in lung cancer

nirsevimab recommended for infant RSV protection

AstraZeneca agreement with Quell Therapeutics

Imfinzi improved pCR in gastric and GEJ cancers

Total Voting Rights

Block listing Interim Review

Lynparza approved in US for BRCAm prostate cancer

Imfinzi + Lynparza prolonged PFS in endometrial ca

Directorate Change

Tagrisso plus chemo improved PFS in lung cancer

Director/PDMR Shareholding

Farxiga extended in the US for heart failure